Navigation Links
University Of Colorado Cancer Center Tests Promising New Drug to Treat and Protect Against Radiotherapy-Associated Oral Mucositis
Date:3/13/2013

Aurora, CO (PRWEB) March 13, 2013

In some cancer patients treated with radiation, the mouth sores known as oral mucositis become so severe that feeding tubes are required for nutrition and narcotics are needed for pain. In fact, 40-70 percent of patients treated with upper-body radiation develop the condition to some degree. Currently, there is no FDA approved treatment. A University of Colorado Cancer Center study published this week in the journal Nature Medicine takes an important step toward changing that.

“We developed a genetically engineered mouse that produces a protein called Smad7 in the surface layers of its mouth. With this protein expressed, mouse models were dramatically more resistant to the development of oral mucositis than were controls,” says Xiao-Jing Wang, PhD, CU Cancer Center investigator and John S. Gates endowed Chair of Cancer Stem Cell Biology at the Charles C. Gates Center for Regenerative Medicine and Stem Cell Biology.

Wang and collaborators including Qinghong Zhang, PhD, Yosef Refaeli, PhD, and radiation oncologist David Raben, MD, are pursuing further research with the goal of developing Smad7 as a therapeutic agent for human oral mucositis. For example, the group joined Smad7 in with a short peptide that allows the protein to cross through cell membranes, and produced this combination protein from cultured bacteria. When they applied the engineered compound directly to the mouse oral cavity, it both protected against the development of oral mucositis and worked to heal existing ulcers. Importantly, it revived wounded normal cells but not cancer cells, avoiding a major problem of growth factors currently used to promote the cell growth that heals ulcers.

“It’s very reasonable to hope that this line of research will result in a drug that patients can self-administer topically to oral mucositis sores, or use to prevent them altogether, thus significantly improving the quality of life for many cancer patients,” Wang ways.

Additionally, Wang points out that the mouse model engineered to develop human-like oral mucositis in the presence of radiation treatment is a useful tool for studying the disease – offering opportunities to search for biomarkers and test experimental therapies.

This work was supported in part by NIH grants AR061792, DE015953, R01CA115468, R03DA033982, P30CA046934, & the Bioscience Discovery and Evaluation Grant program (BDEG) by The State of Colorado and University of Colorado Technology Transfer Office.

Read the full story at http://www.prweb.com/releases/2013/3/prweb10524195.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Arizona State University engineers aim to improve performance of technology in extreme environments
2. BioRestorative Therapies Signs Material Manufacturing Agreement With University of Utah
3. Causes of Gulf War Illness are complex and vary by deployment area -- Baylor University study
4. HistoRx Licenses Melanoma Assay from Yale University
5. Epitomics, Inc. and University of California, Davis, Complete Star Program for High-Throughput Measurement of Antibody-Antigen Interactions
6. Boulder Diagnostics Licenses Novel Rapid Detection Technology for Homocysteine and Related Compounds from Portland State University
7. Research at Rice University leads to nanotube-based device for communication, security, sensing
8. EUR 1.0 Million Grant Awarded to Exosome Diagnostics and Ludwig Maximilian University from German Federal Ministry for Education and Research to Develop Biofluid-Derived Exosome Diagnostics
9. Valkee and University of Oulu Publish the First Clinical Trial on Bright Light Therapy Channeled via ear Canals in Seasonal Depression
10. Oxitec Responds to University of Panamas Forum on Transgenic Mosquitoes
11. Intellect Neurosciences Enters Collaboration Agreement with Leading Alzheimers Research Group at University of California Irvine to Test First in Class Dual Target Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita Politecnica ... in people with peritoneal or pleural mesothelioma. Their findings are the subject of a ... , Diagnostic biomarkers are signposts in the blood, lung fluid or tissue of ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... is pleased to announce the launch of their brand, UP4™ Probiotics, into Target ... over 35 years, is proud to add Target to its list of well-respected ...
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
Breaking Biology Technology:
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted ... quarter of 2015 The gross margin was 49% (27) ... the operating margin was 40% (-13) Earnings per share ... operations was SEK 249.9 M (21.2) , Outlook   ... M. The operating margin for 2016 is estimated to ...
(Date:4/15/2016)... April 15, 2016  A new partnership announced ... accurate underwriting decisions in a fraction of the ... priced and high-value life insurance policies to consumers ... With Force Diagnostics, rapid testing (A1C, Cotinine ... readings (blood pressure, weight, pulse, BMI, and activity ...
(Date:3/31/2016)... Florida , March 31, 2016 ... ) ("LegacyXChange" or the "Company") LegacyXChange ... potential users of its soon to be launched online ... ( https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also provide potential ... use of DNA technology to an industry that is ...
Breaking Biology News(10 mins):